Trial
NCT04042727
Controlling Rapid Atrial Fibrillation With Dexmedetomidine
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Stony Brook University
Collaborators
—
Condition
Rapid Atrial Fibrillation
Intervention
Dexmedetomidine Hydrochloride
Why stopped
Futility, as a result of COVID-19 impact
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-04